> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Flu, COVID-19 and RSV Rise Together as CDC Tracks Heavy Winter Hospital Burden and JN.1 Reaches 39%–50% of U.S. Variants
- URL: https://www.theamericanquorum.com/taq-historical-2023-12-30-healthcare/
- Published: 2023-12-31T04:59:00.000Z
- Updated: 2023-12-31T04:59:00.000Z
- Description: CDC data show influenza, COVID-19 and RSV activity rising together at year-end, while JN.1 grows to an estimated 39%–50% of U.S. coronavirus variants and vaccine uptake remains uneven.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-09-01 09:53

Influenza, COVID-19 and respiratory syncytial virus are all contributing to a rising winter respiratory-disease burden as 2023 closes, with emergency visits and hospitalizations increasing across much of the country and the fast-growing JN.1 coronavirus variant accounting for an estimated 39%–50% of U.S. infections.

The Centers for Disease Control and Prevention’s latest [respiratory-virus activity assessment](https://stacks.cdc.gov/view/cdc/138723?ref=theamericanquorum.com), published Friday, shows elevated illness in multiple regions as Americans move through the holiday period. The pattern is not a single-virus wave. Influenza activity is climbing sharply, COVID-19 remains a major source of severe disease, and RSV continues to send infants, young children and older adults to hospitals.

CDC cautioned that holiday reporting delays can temporarily distort the newest surveillance data, particularly for the week ending December 23\. Even with that limitation, several independent systems point in the same direction: respiratory-virus activity is increasing, and the burden is falling most heavily on age groups and patients already at highest risk of complications.

## Hospitalizations show three viruses moving at once

CDC’s December 29 [hospitalization surveillance](https://stacks.cdc.gov/view/cdc/138720?ref=theamericanquorum.com) shows COVID-19, influenza and RSV all contributing to inpatient demand. COVID-19 continues to produce the largest number of hospital admissions among the three nationally, while influenza admissions have accelerated as seasonal flu activity spreads. RSV hospitalization rates remain especially important for infants and older adults.

The agency’s companion report on [severe respiratory illness](https://stacks.cdc.gov/view/cdc/138722?ref=theamericanquorum.com) emphasizes that the risk is not evenly distributed. Older adults, very young children, people with chronic medical conditions and those with weakened immune systems remain more likely to develop serious disease. Those differences make vaccination, early testing and timely antiviral treatment particularly consequential during periods when several pathogens are circulating simultaneously.

Emergency departments are showing the same seasonal pressure. CDC’s [emergency-visit surveillance](https://stacks.cdc.gov/view/cdc/138721?ref=theamericanquorum.com) tracks increasing visits for diagnosed influenza, COVID-19 and RSV, providing a more immediate signal than some hospitalization datasets. Emergency-department data are especially useful during holiday weeks because they can reveal changes in acute illness even while other reporting systems are incomplete.

## Influenza accelerates heading into January

The latest [FluView report](https://stacks.cdc.gov/view/cdc/138732?ref=theamericanquorum.com), covering the week ending December 23, indicates that seasonal influenza activity is elevated nationally and continues to rise. Outpatient visits for respiratory illness are above the national baseline, and multiple jurisdictions are reporting high or very high influenza-like illness activity.

Influenza’s rise matters because the 2023-24 season is still early enough for substantial additional transmission. Seasonal flu commonly peaks between December and February, though the exact timing varies. The current increase therefore does not by itself indicate how severe the full season will become, but it does mean hospitals and clinics are entering January with a growing flu caseload layered onto continuing COVID-19 and RSV activity.

For clinicians, the overlapping symptoms make laboratory diagnosis more important in higher-risk patients. Fever, cough, fatigue and shortness of breath can occur with all three infections. Because antivirals are available for influenza and COVID-19 and work best when started promptly in appropriate patients, identifying the cause of illness can directly affect treatment decisions.

## JN.1 becomes the dominant coronavirus lineage

COVID-19’s winter increase is occurring as JN.1 rapidly expands. In its December 22 [JN.1 update](https://restoredcdc.org/www.cdc.gov/ncird/whats-new/jn.1-update-2023-12-22.html?ref=theamericanquorum.com), CDC estimated that the lineage represented 39%–50% of circulating U.S. variants for the two-week period ending December 23, up sharply from earlier estimates.

JN.1 is closely related to BA.2.86 and carries an additional spike-protein change. Its rapid growth suggests a transmission advantage, but CDC said there was no evidence at this point that JN.1 causes more severe disease than other circulating variants. The agency also said existing tests and treatments are expected to remain effective, and updated COVID-19 vaccines are expected to increase protection against JN.1 as well as other currently circulating lineages.

That distinction is important. A variant can drive more total illness by spreading efficiently even if the probability of severe disease for an individual infection does not increase. With millions of people exposed during holiday travel and indoor gatherings, a more transmissible lineage can still generate substantial hospital burden.

## Vaccination coverage remains an important vulnerability

The winter surge is arriving with uneven vaccine uptake. A December 22 CDC [Morbidity and Mortality Weekly Report](https://www.cdc.gov/mmwr/volumes/72/wr/mm7251a4.htm?ref=theamericanquorum.com) estimated that, as of December 9, 42.2% of U.S. adults had received the current seasonal influenza vaccine, 18.3% had received the updated 2023-24 COVID-19 vaccine, and 17.0% of adults age 60 and older had received an RSV vaccine.

Those numbers are not directly comparable because recommendations differ by product and age group, but together they show that large shares of eligible adults remain unvaccinated against respiratory pathogens that are now circulating widely. The RSV vaccines are new this season and recommended for adults 60 and older through shared clinical decision-making, while updated COVID-19 vaccination is recommended broadly for people six months and older.

CDC has repeatedly emphasized that vaccination is primarily a tool for reducing severe outcomes rather than guaranteeing that every infection is prevented. That makes coverage especially relevant as hospitals manage simultaneous waves of disease. Even modest reductions in hospitalization risk can translate into meaningful capacity benefits when community transmission is high.

## The year ends with a familiar but more complex winter challenge

The United States enters 2024 with a respiratory season fundamentally different from the first pandemic winters. COVID-19 is no longer the only major national respiratory threat receiving intense surveillance; it is now circulating alongside resurgent seasonal influenza and RSV, with vaccines or preventive products available for all three.

At the same time, the practical challenge for health systems remains substantial. Multiple pathogens can rise together, immunity varies widely by age and prior exposure, and holiday behavior can accelerate transmission just as reporting becomes less complete. CDC’s year-end surveillance therefore supports a cautious interpretation: the newest weekly numbers may change as delayed reports arrive, but the broader direction is clear.

Respiratory illness is rising across the country, JN.1 has become the leading coronavirus lineage, influenza is accelerating, and vulnerable patients are again bearing a disproportionate share of serious disease. The next several weeks will show whether the combined burden approaches the peaks of recent winters or begins to level, but hospitals are entering January with all three major respiratory viruses active at once.